246 related articles for article (PubMed ID: 18004087)
1. Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy.
Ofotokun I; Smithson SE; Lu C; Easley KA; Lennox JL
Am J Med Sci; 2007 Nov; 334(5):334-41. PubMed ID: 18004087
[TBL] [Abstract][Full Text] [Related]
2. HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
Su S; Fairley CK; Sasadeusz J; He J; Wei X; Zeng H; Jing J; Mao L; Chen X; Zhang L
J Med Virol; 2018 Mar; 90(3):518-525. PubMed ID: 29091279
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B and C co-infection among HIV-infected adults while on antiretroviral treatment: long-term survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia.
van Griensven J; Phirum L; Choun K; Thai S; De Weggheleire A; Lynen L
PLoS One; 2014; 9(2):e88552. PubMed ID: 24533106
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.
Nelson M; Amaya G; Clumeck N; Arns da Cunha C; Jayaweera D; Junod P; Li T; Tebas P; Stevens M; Buelens A; Vanveggel S; Boven K;
J Antimicrob Chemother; 2012 Aug; 67(8):2020-8. PubMed ID: 22532465
[TBL] [Abstract][Full Text] [Related]
5. Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.
Mbougua JB; Laurent C; Kouanfack C; Bourgeois A; Ciaffi L; Calmy A; Gwet H; Koulla-Shiro S; Ducos J; Mpoudi-Ngolé E; Molinari N; Delaporte E
BMC Public Health; 2010 Mar; 10():105. PubMed ID: 20193053
[TBL] [Abstract][Full Text] [Related]
6. Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort.
Di Biagio A; Nicolini LA; Lorenzini P; Puoti M; Antinori A; Cozzi-Lepri A; Gori A; Vecchiet J; Mussini C; Andreoni M; Viscoli C; d'Arminio Monforte A; For The Icona Foundation Study Group
HIV Clin Trials; 2014; 15(4):151-60. PubMed ID: 25143024
[TBL] [Abstract][Full Text] [Related]
7. Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria.
Agbaji O; Thio CL; Meloni S; Graham C; Muazu M; Nimzing L; Idoko J; Sankalé JL; Ekong E; Murphy R; Kanki P; Hawkins C
J Acquir Immune Defic Syndr; 2013 Feb; 62(2):204-7. PubMed ID: 23196830
[TBL] [Abstract][Full Text] [Related]
8. Elevated alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus coinfection.
Alghamdi S; Alrbiaan A; Alaraj A; Alhuraiji A; Alghamdi M; Alrajhi A
Ann Saudi Med; 2016; 36(4):288-91. PubMed ID: 27478915
[TBL] [Abstract][Full Text] [Related]
9. Baseline CD4 cell counts and outcomes among adult treatment naive HIV patients after taking fixed dose combination GPO-VIR-S and GPO-VIR-Z in Thailand.
Kyaw NL; Thanachartwet V; Kiertiburanakul S; Desakorn V; Chamnanchanunt S; Chierakul W; Manosuthi W; Pitisuttithum P; Sungkanuparph S
Southeast Asian J Trop Med Public Health; 2013 Mar; 44(2):232-43. PubMed ID: 23691633
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.
den Brinker M; Wit FW; Wertheim-van Dillen PM; Jurriaans S; Weel J; van Leeuwen R; Pakker NG; Reiss P; Danner SA; Weverling GJ; Lange JM
AIDS; 2000 Dec; 14(18):2895-902. PubMed ID: 11153671
[TBL] [Abstract][Full Text] [Related]
11. Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation.
Meraviglia P; Schiavini M; Castagna A; Viganò P; Bini T; Landonio S; Danise A; Moioli MC; Angeli E; Bongiovanni M; Hasson H; Duca P; Cargnel A
HIV Med; 2004 Sep; 5(5):334-43. PubMed ID: 15369508
[TBL] [Abstract][Full Text] [Related]
12. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
Torti C; Costarelli S; De Silvestri A; Quiros-Roldan E; Lapadula G; Cologni G; Paraninfo G; Castelnuovo F; Puoti M; Carosi G;
Drug Saf; 2007; 30(12):1161-9. PubMed ID: 18035868
[TBL] [Abstract][Full Text] [Related]
13. Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients.
Lapadula G; Costarelli S; Chatenoud L; Castelli F; Astuti N; Di Giambenedetto S; Quiros-Roldan E; Sighinolfi L; Ladisa N; Di Pietro M; Zoncada A; Di Filippo E; Gori A; Nasta P; Torti C;
J Acquir Immune Defic Syndr; 2015 Jul; 69(3):312-8. PubMed ID: 25723139
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
Matthews GV; Avihingsanon A; Lewin SR; Amin J; Rerknimitr R; Petcharapirat P; Marks P; Sasadeusz J; Cooper DA; Bowden S; Locarnini S; Ruxrungtham K; Dore GJ
Hepatology; 2008 Oct; 48(4):1062-9. PubMed ID: 18697216
[TBL] [Abstract][Full Text] [Related]
15. Immunological characterisation of an unmasking TB-IRIS case.
Wilkinson KA; Meintjes G; Seldon R; Goliath R; Wilkinson RJ
S Afr Med J; 2012 Mar; 102(6):512-7. PubMed ID: 22668952
[TBL] [Abstract][Full Text] [Related]
16. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection.
Kovari H; Ledergerber B; Battegay M; Rauch A; Hirschel B; Foguena AK; Vernazza P; Bernasconi E; Mueller NJ; Weber R
Clin Infect Dis; 2010 Feb; 50(4):502-11. PubMed ID: 20085465
[TBL] [Abstract][Full Text] [Related]
17. Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort.
Torti C; Lapadula G; Puoti M; Casari S; Uccelli MC; Cristini G; Bella D; Pastore G; Ladisa N; Minoli L; Sotgiu G; Caputo SL; Bonora S; Carosi G
J Acquir Immune Defic Syndr; 2006 Feb; 41(2):180-5. PubMed ID: 16394850
[TBL] [Abstract][Full Text] [Related]
18. The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi.
Andreotti M; Pirillo MF; Liotta G; Jere H; Maulidi M; Sagno JB; Luhanga R; Amici R; Mancini MG; Gennaro E; Marazzi MC; Vella S; Giuliano M; Palombi L; Mancinelli S
BMC Infect Dis; 2014 Apr; 14():180. PubMed ID: 24708626
[TBL] [Abstract][Full Text] [Related]
19. CD4+ T Cell Recovery and Hepatitis B Virus Coinfection in HIV-Infected Patients from Côte d'Ivoire Initiating Antiretroviral Therapy.
Houghtaling L; Moh R; Abdou Chekaraou M; Gabillard D; Anglaret X; Eholié SP; Zoulim F; Danel C; Lacombe K; Boyd A
AIDS Res Hum Retroviruses; 2018 May; 34(5):439-445. PubMed ID: 29466862
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and predictors of liver disease in HIV-infected children and adolescents.
Pokorska-Śpiewak M; Stańska-Perka A; Popielska J; Ołdakowska A; Coupland U; Zawadka K; Szczepańska-Putz M; Marczyńska M
Sci Rep; 2017 Sep; 7(1):12309. PubMed ID: 28951598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
